Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual...

Inverness Medical Innovations Declares Dividend on its Series B Convertible
Perpetual Preferred Stock

WALTHAM, Mass., March 30 /PRNewswire-FirstCall/ -- Inverness Medical
Innovations, Inc. (NYSE: IMA), a global leader in enabling individuals to take
charge of their health at home through the merger of rapid diagnostics and
health management, has declared a dividend of $3.00 per share on its Series B
Convertible Perpetual Preferred Stock (NYSE: IMA-PB). The dividend will be
paid in shares of Series B stock in an amount per share equal to the quotient
of (a) $3.00 divided by (b) 97% of the average of the volume-weighted average
price per share of the Series B stock on the New York Stock Exchange for each
of the five consecutive trading days ending on the second trading day
immediately prior to the record date of the dividend. Inverness will pay cash
in lieu of any fractional shares resulting from the dividend. The dividend is
payable on April 15, 2009 to holders of record of Series B stock at the close
of business on April 1, 2009.

Such payment will cover the amount of all dividends accrued from January 1,
2009 through March 31, 2009.

For more information about Inverness Medical Innovations, please visit our
website at http://www.invernessmedical.com.

By developing new capabilities in near-patient diagnosis, monitoring and
health management, Inverness Medical Innovations enables individuals to take
charge of improving their health and quality of life. Inverness' global
leading products and services, as well as its new product development efforts,
focus on infectious disease, cardiology, oncology, drugs of abuse and women's
health. Inverness is headquartered in Waltham, Massachusetts.

SOURCE Inverness Medical Innovations

Doug Guarino, Director of Corporate Relations of Inverness Medical
Innovations, +1-781-647-3900